United Therapeutics Corp. (UTHR) Tops Q1 EPS Views
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $487.61 -0.54%
Revenue Growth %: -1.2%
Financial Fact:
Net product sales: 408.2M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -1.2%
Financial Fact:
Net product sales: 408.2M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
United Therapeutics Corp. (Nasdaq: UTHR) reported Q1 non-GAAP EPS of $1.29, $0.65 better than the analyst estimate of $0.64. Revenue for the quarter came in at $165.6 million versus the consensus estimate of $178.02 million.
United Therapeutics reported non-GAAP EPS of $1.13 in Q210.
United Therapeutics reported non-GAAP EPS of $1.13 in Q210.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA accepts United Therapeutics' sNDA for Tyvaso to treat IPF
- Oxford Industries (OXM) Tops Q2 EPS by 4c; offers guidance
- BRP Inc. (DOO) Reports Q2 Loss of Cd$0.18
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
